28 October 2015 - Today the U.S. Food and Drug Administration expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery.

For more details, go to: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm469944.htm